Home » Healthcare » Pharmaceuticals » Oncology Small Molecule Drug Market

Oncology Small Molecule Drug Market By Drug Class (Chemotherapy Drugs, Alkylating Agents, Antimetabolites, Other Drugs, Targeted Therapy Drug, Proteasome Inhibitors, Tyrosine Kinase Inhibitors, TOR inhibitors, Others, Hormonal Therapy) By Indication (NSCLC, Renal Cell Carcinoma, Breast Cancer, Prostate Cancer, Multiple Myeloma, Melanoma, Lymphoma, Leukaemia, Others)–Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global oncology small molecule drug market is segmented by drug class, indication, RoA, distribution channel, and region. Targeted therapy drugs holds the largest market share among the drug class segment; breast cancer accounted for the largest indication segment. Injectables dominated the RoA segment, while hospital pharmacies were the most popular distribution channel. North America is leading the market growth.

The global oncology small molecule drug market has been driven by the increasing prevalence of cancer, which has improved the demand for oncology small molecule drugs across the globe. Additionally, a trend Advances in molecular biology, genomics, and drug discovery techniques has emerged in recent years. However, the Adverse effects of drugs on the human body may restrain the market’s overall growth.

Nonetheless, the global oncology small molecule drug market offers significant growth opportunities, such as a growing focus on R&D to increase the adoption of advanced drug therapies significant opportunity for the oncology small molecule drug market. Additionally, regulatory bodies’ increasing approvals of small-molecule cancer drugs have expanded the treatment options available to healthcare providers and patients. These drugs target specific molecular targets involved in cancer development and progression, offering potential benefits such as increased efficacy, reduced side effects, and improved patient outcomes.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

The global oncology small molecule drug market has witnessed steady growth in recent years and is expected to grow at a CAGR of 5.80% between 2023 and 2030. The market was valued at USD 76.5 billion in 2022 and is expected to reach USD 113.51 billion in 2030.

What Are the Main Drivers of The Global Oncology Small Molecule Drug Market?

The global oncology small molecule drug market is driven by several factors, including the Increasing prevalence of cancer, driving the demand for oncology small molecule drugs.

What Are the Major Challenges the Global Oncology Small Molecule Drug Market Faces?

The global oncology small molecule drug market also faces several challenges, such as the high cost of oncology small molecule drug development limiting the market’s growth, particularly for price-sensitive consumers.

What Are the Growth Opportunities in The Global Oncology Small Molecule Drug Market?

The global oncology small molecule drug market offers significant growth opportunities in the growing focus on R&D to increase the adoption of advanced drug therapies.

Executive Summary

Overview of the Global Oncology Small Molecule Drug Market

The global oncology small molecule drug market has steadily grown in recent years. The oncology small molecule drugs market is prophesied to display phenomenal growth and outperform other available drug therapies for cancer treatment over the forecast period. The advent of small molecular drugs for cancer therapeutics is groundbreaking and transforming the entire cancer therapy landscape.

Market Definition

The global oncology small molecule drug market refers to the worldwide industry encompassing the research, development, production, and commercialization of small molecule drugs for treating various types of cancer. Small molecule drugs are chemical compounds with a low molecular weight that can be orally administered and easily penetrate cell membranes to interact with specific targets within cancer cells.

The market includes pharmaceutical companies, biotechnology firms, research institutions, and healthcare providers involved in developing, manufacturing, and distributing small molecule drugs for oncology. These drugs inhibit specific molecular targets or pathways in cancer growth, proliferation, and survival. They can be used as standalone therapies or combined with other treatment modalities like surgery, radiation therapy, or immunotherapy.

Market Insights

The global demand for oncology small molecule drugs was valued at USD 76.5 Billion in 2022 and is expected to reach USD 113.51 Billion in 2030, growing at a CAGR of 5.80% between 2023 and 2030.
Targeted therapy drugs are the leading segment in the drug class segment and held the largest revenue share in terms of value in 2022
while the chemotherapy drugs segment will likely exhibit the fastest CAGR during the forecast period.
Brest cancer holds the largest market share among the indication
Prostate cancer holds the fastest-growing CAGR among the indication type over the forecast period.
Injectables segment held the highest market share among the RoA.
Hospital pharmacies among distribution channel is expected to post the highest CAGR during the forecast period among distribution channel.
Retail pharmacies are leading the market share with more than 25% share in 2022 among the distribution channel.
North America is fuelling the growth of the Oncology Small Molecule Drug industry with nearly a two-fifth share in 2022, while Europe and Asia-pacific collectively accounted for just nearly under 55% share in 2022. Asia-pacific held over 22% share in 2022.
Companies operating in this market conduct extensive research and development efforts to identify and validate potential drug targets, discover and optimize small molecule drug candidates, conduct preclinical and clinical trials, and seek regulatory approvals. Successful drugs that demonstrate safety and efficacy in clinical trials are manufactured and marketed globally.

Segmentation by Drug Class

Targeted therapy drug material type is the leading segment and largest share in value in 2022.
Chemotherapy drug material will likely exhibit the fastest CAGR during the forecast period.
Hormonal therapy segment of the drug class holds the lowest market share

Segmentation by Indication

Breast cancer is the leading segment and largest share in value in 2022.
Prostate cancer handles will likely exhibit the fastest CAGR during the forecast period.
Renal cell carcinoma segment of the indication holds the lowest market share

Segmentation by RoA

Injectables is the leading segment and largest share in value in 2022, and it will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Distribution Channel

The hospital pharmacies segment governs the demand for the oncology small molecule drug industry in the world
Retail pharmacies hold a massive share and are also expected to grow at a rapid CAGR.
Online pharmacies segment of the distribution channel holds the lowest market share

Segmentation by Region

Asia Pacific was fueling the growth of the Oncology Small Molecule Drug industry with a nearly two-fifths share in 2022.
North America and Europe collectively account for nearly under 55% share in 2022, with Europe holding over 22% share in the same year.
The rest of the world, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for oncology small molecule drugs.

The global oncology drug delivery market has been experiencing significant growth, driven by factors such as a growing pipeline of small molecule drugs; pharmaceutical companies and research institutions have been actively pursuing the development of small molecule drugs for various cancer types. The pipeline of oncology small molecule drugs is robust, focusing on novel targets, combination therapies, and overcoming drug resistance. The expanding pipeline indicates a strong commitment to advancing cancer treatment options and offers growth potential for the market.

In China, the increasing prevalence of cancer cases across the country is expected to drive market growth over the forecast period. For instance, according to the report by the National Institute of Biotechnology Information in February 2022, China is expected to witness around 4,820,000 new cancer diagnoses and 3,210,000 cancer-related deaths, while the United States is projected to have approximately 2,370,000 new cancer diagnoses and 640,000 cancer-related deaths.

The increasing government initiative for developing new drugs in the US is driving market growth nationwide. For instance, in June 2023, The U.S. Food and Drug Administration (FDA) introduced a voluntary pilot program to aid clinicians in selecting appropriate cancer treatments for patients by utilizing certain oncology drug products alongside specific in vitro diagnostic tests. This initiative aims to address safety concerns related to poorly performing laboratory-developed tests. The FDA’s current policy recognizes in vitro companion diagnostic tests as crucial for the safe and effective use of complementary treatments. In limited cases, the FDA may approve life-saving treatments that require in vitro companion diagnostics, even if these diagnostics still need to obtain marketing authorization. While laboratory-developed tests (LDTs) have traditionally operated under an enforcement discretion approach, exceptions are made during public health emergencies.

However, the global oncology small molecule drug market is experiencing significant growth due to the increasing incidence of cancer, the development of targeted therapies, advancements in drug discovery and development, expanding market presence in emerging regions, collaborations, regulatory support, and patent expirations. This growth is expected to continue as researchers and pharmaceutical companies strive to address the unmet medical needs of cancer patients and improve treatment outcomes.

Increasing Prevalence of Cancer

Cancer incidence rates have been steadily increasing across the globe. Factors such as aging populations, lifestyle changes, environmental factors, and improved cancer detection and diagnosis contribute to this rise. As cancer cases grow, there is a greater need for innovative treatment options, including small-molecule drugs.

Small molecule drugs play a crucial role in targeted cancer therapies. These drugs target and inhibit specific molecular targets or pathways in cancer growth and progression. With the increasing prevalence of cancer, there is a greater emphasis on personalized medicine and targeted therapies. Small molecule drugs are instrumental in addressing the unique molecular characteristics of individual tumors, leading to more effective and precise treatments. For instance, according to the data published by the National Cancer Institute in September 2020, In the year 2020, it was reported that approximately 1,806,590 new cancer cases were diagnosed in the United States, leading to approximately 606,520 deaths from the disease. The most prevalent types of cancer, listed in descending order based on estimated new cases in 2020, included breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer.

Approval of Small Molecule Cancer Drugs by Regulatory Bodies

Regulatory approval is a prerequisite for commercializing and market entry of small molecule cancer drugs. The approval process ensures that drugs meet stringent safety, efficacy, and quality standards before being prescribed to patients. Once approved, pharmaceutical companies can launch their drugs and make them available to healthcare providers and patients, thus driving the market’s growth. Regulatory bodies evaluate the safety and efficacy of small molecule cancer drugs through rigorous preclinical and clinical trial assessments. This validation gives healthcare professionals and patients confidence in the drug’s therapeutic benefits and helps make informed treatment decisions. Assures healthcare providers of their potential effectiveness, driving the adoption of these drugs in clinical practice.

High Cost of Oncology Small Molecule Drug Development

The early stages of drug development require significant investment in research, including target identification and validation, lead compound discovery, and preclinical studies. These costs cover laboratory resources, equipment, personnel, and specialized expertise. Pharmaceutical companies and research institutions allocate substantial funds to support research and development efforts, and these expenses contribute to the overall high cost of drug development. Clinical trials, essential for testing the safety and efficacy of small molecule drugs, are a major contributor to the high cost of drug development. Clinical trials involve recruiting patients, administering treatments, monitoring outcomes, collecting data, and complying with regulatory requirements. The costs associated with trial design, patient recruitment, site management, data analysis, and safety monitoring all contribute to the overall expenses incurred during clinical development.

Growing Focus on R&D to Increase Adoption of Advanced Drug Therapies

Pharmaceutical companies, research institutions, and healthcare organizations invest significant resources into R&D activities to discover, develop, and commercialize innovative small-molecule drugs for cancer treatment. R&D efforts are focused on identifying and validating novel molecular targets involved in cancer development and progression. Advances in genomics, molecular biology, and bioinformatics have provided valuable insights into the molecular mechanisms of cancer, enabling the discovery of new targets for therapeutic intervention. The discovery of novel targets fuels the development of small-molecule drugs tailored to specific cancer subtypes, driving the market’s growth. For instance, according to a report by National Cancer Institute in June 2023, The National Cancer Institute (NCI) has initiated ComboMATCH, a large precision medicine cancer study, to assess the efficacy of new drug combinations targeting specific tumor alterations. This comprehensive endeavor aims to identify potential treatments for further evaluation in larger clinical trials. NCI, an agency of the National Institutes of Health, spearheads this initiative.

Competitive Landscape

Key Players

The global oncology small molecule drug market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

These companies focus on product innovation, expanding their applications, mergers, and acquisitions to stay ahead.

The major players in the global oncology small molecule drug market constantly strive to stay ahead by introducing new products and innovations.

In April 2023, Tavros Therapeutics and OpenBench expanded their collaboration through a new agreement on discovering small molecule modulators for multiple oncology targets. The partnership aims to streamline drug development for cancer therapies and will last for an initial period of 18 months. OpenBench will receive an upfront payment and additional compensation upon successful identification and experimental confirmation of new small molecule chemotypes that meet Tavros’ standards. Tavros will gain exclusive access to OpenBench’s proprietary AI-driven screening technology for cancer targets.

In December 2019, Merck & Co. agreed to acquire rQule for approximately US$ 2.7 billion in cash. This acquisition follows a trend of big pharma acquiring small-molecule-focused cancer drug firms. The deal revolves around ARQ 531, a small molecule that targets Bruton’s tyrosine kinase (BTK), an essential enzyme for B cell development and survival.

Summary of Key Findings

Increasing cancer cases across the globe are driving the demand for Oncology Small Molecule Drugs.

Market segmented by drug class, indication, RoA, distribution channel, and region.
Targeted therapy drug is the most popular segment among the drug class type
Chemotherapy drugs hold the fastest-growing segment globally over the forecast period.
Breast cancer holds the largest market share in 2022 among the indication type.
Prostate cancer is the fastest-growing segment among the indication type.
Injectible RoA holds the highest segment among the RoA segment.
Hospital pharmacies hold the dominant market share among the distribution channel
Retail pharmacies hold the fastest-growing CAGR over the forecast period.

North America is leading market growth; the market is highly competitive with key players including Eli Lilly and Co, Janssen Research and Development LLC, Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., AstraZeneca, HQ Specialty Pharma Corp, and others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Future Outlook

Positive outlook for the global oncology small molecule drug market with significant growth potential in the North American region
The rising incidence of cancer has become a significant health concern, creating a strong demand for effective treatments.
Challenges like the high cost of oncology small molecule drug development significantly impact the global oncology small molecule drug market. Developing new drugs, particularly in oncology, involves extensive research, rigorous testing, clinical trials, and regulatory processes, which incur substantial expenses.

Segmentation

By Drug Class

Chemotherapy Drugs
Alkylating Agents
Antimetabolites
Other Drugs
Targeted Therapy Drug
Proteasome Inhibitors
Tyrosine Kinase Inhibitors
mTOR inhibitors
Others
Hormonal Therapy

By Indication

NSCLC
Renal Cell Carcinoma
Breast Cancer
Prostate Cancer
Multiple Myeloma
Melanoma
Lymphoma
Leukaemia
Others

By RoA

Oral
Injectables

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Specialty Clinics
Online Pharmacies

By Region

North America
- The US.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Oncology Small Molecule Drug Market
2.2. Global Oncology Small Molecule Drug Market, By Drug Class
2.3. Global Oncology Small Molecule Drug Market, By Indication
2.4. Global Oncology Small Molecule Drug Market, By RoA
2.5. Global Oncology Small Molecule Drug Market, By Distribution Channel
2.6. Global Oncology Small Molecule Drug Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Oncology Small Molecule Drug Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Drug Class
3.5.2. Indication
3.5.3. RoA
3.5.4. Distribution Channel
3.5.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Hormonal Therapy

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Oncology Small Molecule Drug Market, By Drug Class
7.1. Global Oncology Small Molecule Drug Market Overview, by Drug Class
7.1.1. Global Oncology Small Molecule Drug Market Revenue Share, By Drug Class, 2022 Vs 2030 (in %)
7.2. Chemotherapy Drugs
7.2.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
7.2.1.1. Alkylating Agents
7.2.1.2. Antimetabolites
7.2.1.3. Other Drugs
7.3. Targeted Therapy Drugs
7.3.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
7.3.1.1. Proteasome Inhibitors
7.3.1.2. Tyrosine Kinase Inhibitors
7.3.1.3. mTOR inhibitors
7.3.1.4. Others
7.4. Hormonal Therapy
7.4.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)

8. Global Oncology Small Molecule Drug Market, By Indication
8.1. Global Oncology Small Molecule Drug Market Overview, by Indication
8.1.1. Global Oncology Small Molecule Drug Market Revenue Share, By Indication, 2022 Vs 2030 (in %)
8.2. NSCLC
8.2.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.3. Automatic
8.3.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.4. Breast Cancer
8.4.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.5. Prostate Cancer
8.5.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.6. Multiple Myeloma
8.6.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.7. Melanoma
8.7.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.8. Lymphoma
8.8.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.9. Leukaemia
8.9.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
8.10. Others
8.10.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)

9. Global Oncology Small Molecule Drug Market, By RoA
9.1. Global Oncology Small Molecule Drug Market Overview, by RoA
9.1.1. Global Oncology Small Molecule Drug Market Revenue Share, By RoA, 2022 Vs 2030 (in %)
9.2. Oral
9.2.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
9.3. Injectables
9.3.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)

10. Global Oncology Small Molecule Drug Market, By Distribution Channel
10.1. Global Oncology Small Molecule Drug Market Overview, by Distribution Channel
10.1.1. Global Oncology Small Molecule Drug Market, By Distribution Channel, 2022 vs 2030 (in %)
10.2. Hospital Pharmacies
10.2.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
10.3. Retail Pharmacies
10.3.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
10.4. Specialty Clinics
10.4.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)
10.5. Online Pharmacies
10.5.1. Global Oncology Small Molecule Drug Market, By Region, 2017-2030 (US$ Bn)

11. Global Oncology Small Molecule Drug Market, By Region
11.1. Global Oncology Small Molecule Drug Market Overview, by Region
11.1.1. Global Oncology Small Molecule Drug Market, By Region, 2022 vs 2030 (in%)
11.2. Drug Class
11.2.1. Global Oncology Small Molecule Drug Market, By Drug Class, 2017-2030 (US$ Bn)
11.3. Indication
11.3.1. Global Oncology Small Molecule Drug Market, By Indication, 2017-2030 (US$ Bn)
11.4. RoA
11.4.1. Global Oncology Small Molecule Drug Market, By RoA, 2017-2030 (US$ Bn)
11.5. Distribution Channel
11.5.1. Global Oncology Small Molecule Drug Market, By Distribution Channel, 2017-2030 (US$ Bn)

12. North America Oncology Small Molecule Drug Market Analysis
12.1. North America Oncology Small Molecule Drug Market, by Drug Class, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. North America Oncology Small Molecule Drug Market, by Indication, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Oncology Small Molecule Drug Market, by RoA, 2017-2030(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2030(US$ Bn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Oncology Small Molecule Drug Market, by Country, 2017-2030 (US$ Bn)
12.5.1. North America Oncology Small Molecule Drug Market, by Country, 2022 Vs 2030 (in%)
12.5.2. U.S.
12.5.2.1. U.S. Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.2.2. U.S. Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
12.5.2.3. U.S. Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
12.5.2.4. U.S. Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
12.5.2.5. U.S. Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
12.5.3. Canada
12.5.3.1. Canada Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.3.2. Canada Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
12.5.3.3. Canada Oncology Small Molecule Drug, By Indication Type, 2017-2030 (US$ Bn)
12.5.3.4. Canada Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
12.5.3.5. Canada Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
12.5.4. Mexico
12.5.4.1. Mexico Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.4.2. Mexico Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
12.5.4.3. Mexico Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
12.5.4.4. Mexico Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
12.5.4.5. Mexico Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)

13. Europe Oncology Small Molecule Drug Market Analysis
13.1. Europe Oncology Small Molecule Drug Market, by Drug Class, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Europe Oncology Small Molecule Drug Market, by Indication, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Oncology Small Molecule Drug Market, by RoA, 2017-2030(US$ Bn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2030(US$ Bn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Oncology Small Molecule Drug Market, by Country, 2017-2030 (US$ Bn)
13.5.1. Europe Oncology Small Molecule Drug Market, by Country, 2022 Vs 2030 (in%)
13.5.2. Germany
13.5.2.1. Germany Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.2.2. Germany Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.2.3. Germany Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.2.4. Germany Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.2.5. Germany Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
13.5.3. France
13.5.3.1. France Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.3.2. France Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.3.3. France Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.3.4. France Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.3.5. France Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
13.5.4. UK
13.5.4.1. UK Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.4.2. UK Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.4.3. UK Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.4.4. UK Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.4.5. UK Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
13.5.5. Italy
13.5.5.1. Italy Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.5.2. Italy Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.5.3. Italy Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.5.4. Italy Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.5.5. Italy Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
13.5.6. Spain
13.5.6.1. Spain Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.6.2. Spain Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.6.3. Spain Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.6.4. Spain Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.6.5. Spain Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
13.5.7. Rest of Europe
13.5.7.1. Rest of Europe Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.5.7.2. Rest of Europe Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
13.5.7.3. Rest of Europe Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
13.5.7.4. Rest of Europe Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
13.5.7.5. Rest of Europe Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)

14. Asia Pacific Oncology Small Molecule Drug Market Analysis
14.1. Asia Pacific Oncology Small Molecule Drug Market, by Drug Class, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Oncology Small Molecule Drug Market, by RoA, 2017-2030(US$ Bn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2030(US$ Bn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Oncology Small Molecule Drug Market, by Country, 2017-2030 (US$ Bn)
14.5.1. Asia Pacific Oncology Small Molecule Drug Market, by Country, 2022 Vs 2030 (in%)
14.5.2. China
14.5.2.1. China Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.2.2. China Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.2.3. China Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.2.4. China Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.2.5. China Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
14.5.3. Japan
14.5.3.1. Japan Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.3.2. Japan Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.3.3. Japan Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.3.4. Japan Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.3.5. Japan Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
14.5.4. India
14.5.4.1. India Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.4.2. India Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.4.3. India Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.4.4. India Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.4.5. India Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
14.5.5. South Korea
14.5.5.1. South Korea Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.5.2. South Korea Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.5.3. South Korea Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.5.4. South Korea Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.5.5. South Korea Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
14.5.6. South-East Asia
14.5.6.1. South-East Asia Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.6.2. South-East Asia Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.6.3. South-East Asia Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.6.4. South-East Asia Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.6.5. South-East Asia Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
14.5.7. Rest of Asia Pacific
14.5.7.1. Rest of Asia Pacific Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.5.7.2. Rest of Asia Pacific Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
14.5.7.3. Rest of Asia Pacific Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
14.5.7.4. Rest of Asia Pacific Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
14.5.7.5. Rest of Asia Pacific Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)

15. Latin America Oncology Small Molecule Drug Market Analysis
15.1. Latin America Oncology Small Molecule Drug Market, by Drug Class, 2017-2030(US$ Bn)
15.1.1. Overview
15.1.2. SRC Analysis
15.2. Latin America Oncology Small Molecule Drug Market, by Indication, 2017-2030(US$ Bn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Oncology Small Molecule Drug Market, by RoA, 2017-2030(US$ Bn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2030(US$ Bn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Oncology Small Molecule Drug Market, by Country, 2017-2030 (US$ Bn)
15.5.1. Latin America Oncology Small Molecule Drug Market, by Country, 2022 Vs 2030 (in%)
15.5.2. Brazil
15.5.2.1. Brazil Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.5.2.2. Brazil Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
15.5.2.3. Brazil Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
15.5.2.4. Brazil Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
15.5.2.5. Brazil Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
15.5.3. Argentina
15.5.3.1. Argentina Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.5.3.2. Argentina Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
15.5.3.3. Argentina Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
15.5.3.4. Argentina Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
15.5.3.5. Argentina Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
15.5.4. Rest of Latin America
15.5.4.1. Rest of Latin America Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.5.4.2. Rest of Latin America Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
15.5.4.3. Rest of Latin America Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
15.5.4.4. Rest of Latin America Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
15.5.4.5. Rest of Latin America Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)

16. Middle East and Africa Oncology Small Molecule Drug Market Analysis
16.1. Middle East and Africa Oncology Small Molecule Drug Market, by Drug Class, 2017-2030(US$ Bn)
16.1.1. Overview
16.1.2. SRC Analysis
16.2. Middle East and Africa Oncology Small Molecule Drug Market, by Indication, 2017-2030(US$ Bn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East and Africa Oncology Small Molecule Drug Market, by RoA, 2017-2030(US$ Bn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East and Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2030(US$ Bn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East and Africa Oncology Small Molecule Drug Market, by Country, 2017-2030 (US$ Bn)
16.5.1. Middle East and Africa Oncology Small Molecule Drug Market, by Country, 2022 Vs 2030 (in%)
16.5.2. GCC Countries
16.5.2.1. GCC Countries Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.5.2.2. GCC Countries Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
16.5.2.3. GCC Countries Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
16.5.2.4. GCC Countries Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
16.5.2.5. GCC Countries Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
16.5.3. South Africa
16.5.3.1. South Africa Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.5.3.2. South Africa Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
16.5.3.3. South Africa Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
16.5.3.4. South Africa Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
16.5.3.5. South Africa Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)
16.5.4. Rest of Middle East and Africa
16.5.4.1. Rest of Middle East and Africa Oncology Small Molecule Drug Market Estimates and Forecast, 2017-2030 (US$ Bn)
16.5.4.2. Rest of Middle East and Africa Oncology Small Molecule Drug, By Drug Class, 2017-2030 (US$ Bn)
16.5.4.3. Rest of Middle East and Africa Oncology Small Molecule Drug, By Indication, 2017-2030 (US$ Bn)
16.5.4.4. Rest of Middle East and Africa Oncology Small Molecule Drug, By RoA, 2017-2030 (US$ Bn)
16.5.4.5. Rest of Middle East and Africa Oncology Small Molecule Drug, By Distribution Channel, 2017-2030 (US$ Bn)

17. Company Profiles
17.1. Otsuka Pharmaceutical Co. Ltd
17.1.1. Company Overview
17.1.2. Product /Services Portfolio
17.1.3. Geographical Presence
17.1.4. Financial Summary
17.1.4.1. Market Revenue and Net Profit (2019-2022)
17.1.4.2. Business Segment Revenue Analysis
17.1.4.3. Geographical Revenue Analysis
17.2. sEli Lilly and Co
17.3. Janssen Research and Development LLC
17.4. Novartis AG, Pfizer Inc.
17.5. SANOFI AVENTIS US LLC
17.6. Baxter Healthcare Corp.
17.7. Emcure Pharmaceuticals Ltd.
17.8. AstraZeneca
17.9. Kyowa Kirin Inc.
17.10. HQ Specialty Pharma Corp

List of Figures
FIG. 1 Global Oncology Small Molecule Drug Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Oncology Small Molecule Drug Market Segmentation
FIG. 4 Global Oncology Small Molecule Drug Market, by Drug Class, 2022 (US$ Bn)
FIG. 5 Global Oncology Small Molecule Drug Market, by Indication, 2022 (US$ Bn)
FIG. 6 Global Oncology Small Molecule Drug Market, by RoA, 2022 (US$ Bn)
FIG. 7 Global Oncology Small Molecule Drug Market, by Distribution Channel, 2022 (US$ Bn)
FIG. 8 Global Oncology Small Molecule Drug Market, by Geography, 2022 (US$ Bn)
FIG. 9 Attractive Investment Proposition, by Drug Class, 2022
FIG. 10 Attractive Investment Proposition, by Indication, 2022
FIG. 11 Attractive Investment Proposition, by RoA, 2022
FIG. 12 Attractive Investment Proposition, by Distribution Channel, 2022
FIG. 13 Attractive Investment Proposition, by Geography, 2022
FIG. 14 Global Market Share Analysis of Key Oncology Small Molecule Drug Market Manufacturers, 2022
FIG. 15 Global Market Positioning of Key Oncology Small Molecule Drug Market Manufacturers, 2022
FIG. 16 Global Oncology Small Molecule Drug Market Value Contribution, By Drug Class, 2022 & 2030 (Value %)
FIG. 17 Global Oncology Small Molecule Drug Market, by Chemotherapy Drugs, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Oncology Small Molecule Drug Market, by Targeted Therapy Drugs, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Oncology Small Molecule Drug Market, by Hormonal Therapy, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Oncology Small Molecule Drug Market Value Contribution, By Indication, 2022 & 2030 (Value %)
FIG. 21 Global Oncology Small Molecule Drug Market, by NSCLC, Value, 2017-2030 (US$ Bn)
FIG. 22 Global Oncology Small Molecule Drug Market, by Renainoma, Value, 2017-2030 (US$ Bn)
FIG. 23 Global Oncology Small Molecule Drug Market, by Breast Cancer, Value, 2017-2030 (US$ Bn)
FIG. 24 Global Oncology Small Molecule Drug Market, by Prostate Cancer, Value, 2017-2030 (US$ Bn)
FIG. 25 Global Oncology Small Molecule Drug Market, by Multiple Myeloma, Value, 2017-2030 (US$ Bn)
FIG. 26 Global Oncology Small Molecule Drug Market, by Melanoma, Value, 2017-2030 (US$ Bn)
FIG. 27 Global Oncology Small Molecule Drug Market, by Lymphona, Value, 2017-2030 (US$ Bn)
FIG. 28 Global Oncology Small Molecule Drug Market, by Leukarmia, Value, 2017-2030 (US$ Bn)
FIG. 29 Global Oncology Small Molecule Drug Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 30 Global Oncology Small Molecule Drug Market Value Contribution, By RoA, 2022 & 2030 (Value %)
FIG. 31 Global Oncology Small Molecule Drug Market, by Oral, Value, 2017-2030 (US$ Bn)
FIG. 32 Global Oncology Small Molecule Drug Market, by Injectables, Value, 2017-2030 (US$ Bn)
FIG. 33 Global Oncology Small Molecule Drug Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)
FIG. 34 Global Oncology Small Molecule Drug Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 35 Global Oncology Small Molecule Drug Market, by Retail Pharmacies, 2017-2030 (US$ Bn)
FIG. 36 Global Oncology Small Molecule Drug Market, by Speciality Clinics, Value, 2017-2030 (US$ Bn)
FIG. 37 Global Oncology Small Molecule Drug Market, by Online Pharmacies, 2017-2030 (US$ Bn)
FIG. 38 North America Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 39 U.S. Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 40 Canada Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 41 Europe Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 42 Germany Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 43 France Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 44 U.K. Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 45 Italy Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 46 Spain Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 47 Rest of Europe Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 48 Asia Pacific Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 49 China Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 50 Japan Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 51 India Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 52 South Korea Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 53 South-East Asia Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 54 Rest of Asia Pacific Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 55 Latin America Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 56 Brazil Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 57 Mexico Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 58 Rest of Latin America Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 59 Middle East & Africa Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 60 GCC Countries Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 61 South Africa Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)
FIG. 62 Rest of Middle East and Africa Oncology Small Molecule Drug Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Oncology Small Molecule Drug Market
TABLE 2 Global Oncology Small Molecule Drug Market: Market Drivers Impact Analysis
TABLE 3 Global Oncology Small Molecule Drug Market: Market Restraints Impact Analysis
TABLE 4 Global Oncology Small Molecule Drug Market, by Competitive Benchmarking, 2022
TABLE 5 Global Oncology Small Molecule Drug Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Oncology Small Molecule Drug Market, by Key Strategies Analysis, 2022
TABLE 7 Global Oncology Small Molecule Drug Market, by Chemotherapy Drugs, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Oncology Small Molecule Drug Market, by Chemotherapy Drugs, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Oncology Small Molecule Drug Market, by Targeted Therapy Drugs, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Oncology Small Molecule Drug Market, by Targeted Therapy Drugs, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Oncology Small Molecule Drug Market, by other, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Oncology Small Molecule Drug Market, by other, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Oncology Small Molecule Drug Market, by NSCLC, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Oncology Small Molecule Drug Market, by NSCLC, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Oncology Small Molecule Drug Market, by Renal Cell Carcinoma, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Oncology Small Molecule Drug Market, by Renal Cell Carcinoma, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Oncology Small Molecule Drug Market, by Breast Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Oncology Small Molecule Drug Market, by Breast Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Oncology Small Molecule Drug Market, by Prostate Cancer, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Oncology Small Molecule Drug Market, by Prostate Cancer, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Oncology Small Molecule Drug Market, by Multiple Myeloma, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Oncology Small Molecule Drug Market, by Multiple Myeloma, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Oncology Small Molecule Drug Market, by Melanoma, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Oncology Small Molecule Drug Market, by Melanoma, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Oncology Small Molecule Drug Market, by Lymphoma, By Region, 2017-2022 (US$ Bn)
TABLE 26 Global Oncology Small Molecule Drug Market, by Lymphoma, By Region, 2023-2030 (US$ Bn)
TABLE 27 Global Oncology Small Molecule Drug Market, by Leukemia, By Region, 2017-2022 (US$ Bn)
TABLE 28 Global Oncology Small Molecule Drug Market, by Leukemia, By Region, 2023-2030 (US$ Bn)
TABLE 29 Global Oncology Small Molecule Drug Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 30 Global Oncology Small Molecule Drug Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 31 Global Oncology Small Molecule Drug Market, by Oral, By Region, 2017-2022 (US$ Bn)
TABLE 32 Global Oncology Small Molecule Drug Market, by Oral, By Region, 2023-2030 (US$ Bn)
TABLE 33 Global Oncology Small Molecule Drug Market, by Injectables, By Region, 2017-2022 (US$ Bn)
TABLE 34 Global Oncology Small Molecule Drug Market, by Injectables, By Region, 2023-2030 (US$ Bn)
TABLE 35 Global Oncology Small Molecule Drug Market, by Hospital Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 36 Global Oncology Small Molecule Drug Market, by Hospital Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 37 Global Oncology Small Molecule Drug Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 38 Global Oncology Small Molecule Drug Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 39 Global Oncology Small Molecule Drug Market, by Specialty Clinics, By Region, 2017-2022 (US$ Bn)
TABLE 40 Global Oncology Small Molecule Drug Market, by Specialty Clinics, By Region, 2023-2030 (US$ Bn)
TABLE 41 Global Oncology Small Molecule Drug Market, by Online Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 42 Global Oncology Small Molecule Drug Market, by Online Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 43 Global Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 44 Global Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 45 Global Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 46 Global Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 47 Global Oncology Small Molecule Drug Market, by Region, 2017-2022 (US$ Bn)
TABLE 48 Global Oncology Small Molecule Drug Market, by Region, 2023-2030 (US$ Bn)
TABLE 49 North America Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 50 North America Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 51 North America Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 52 North America Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 53 North America Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 54 North America Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 55 North America Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 56 North America Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 57 North America Oncology Small Molecule Drug Market, by Country, 2017-2022 (US$ Bn)
TABLE 58 North America Oncology Small Molecule Drug Market, by Country, 2023-2030 (US$ Bn)
TABLE 59 United States Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 60 United States Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 61 United States Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 62 United States Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 63 United States Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 64 United States Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 65 United States Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 66 United States Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 67 Canada Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 68 Canada Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 69 Canada Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 70 Canada Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 71 Canada Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 72 Canada Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 73 Canada Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 74 Canada Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 75 Mexico Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 76 Mexico Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 77 Mexico Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 78 Mexico Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 79 Mexico Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 80 Mexico Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 81 Mexico Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 82 Mexico Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 83 Europe Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 84 Europe Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 85 Europe Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 86 Europe Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 87 Europe Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 88 Europe Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 89 Europe Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 90 Europe Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 91 Europe Oncology Small Molecule Drug Market, by Country, 2017-2022 (US$ Bn)
TABLE 92 Europe Oncology Small Molecule Drug Market, by Country, 2023-2030 (US$ Bn)
TABLE 93 Germany Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 94 Germany Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 95 Germany Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 96 Germany Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 97 Germany Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 98 Germany Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 99 Germany Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 100 Germany Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 101 France Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 102 France Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 103 France Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 104 France Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 105 France Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 106 France Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 107 France Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 108 France Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 109 United Kingdom Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 110 United Kingdom Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 111 United Kingdom Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 112 United Kingdom Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 113 United Kingdom Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 114 United Kingdom Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 115 United Kingdom Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 116 United Kingdom Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 117 Italy Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 118 Italy Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 119 Italy Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 120 Italy Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 121 Italy Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 122 Italy Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 123 Italy Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 124 Italy Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 125 Spain Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 126 Spain Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 127 Spain Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 128 Spain Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 129 Spain Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 130 Spain Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 131 Spain Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 132 Spain Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 133 Rest of Europe Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 134 Rest of Europe Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 135 Rest of Europe Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 136 Rest of Europe Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 137 Rest of Europe Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 138 Rest of Europe Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 139 Rest of Europe Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 140 Rest of Europe Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 141 Asia Pacific Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 142 Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 143 Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 144 Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 145 Asia Pacific Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 146 Asia Pacific Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 147 Asia Pacific Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 148 Asia Pacific Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 149 Asia Pacific Oncology Small Molecule Drug Market, by Country, 2017-2022 (US$ Bn)
TABLE 150 Asia Pacific Oncology Small Molecule Drug Market, by Country, 2023-2030 (US$ Bn)
TABLE 151 China Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 152 China Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 153 China Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 154 China Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 155 China Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 156 China Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 157 China Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 158 China Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 159 Japan Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 160 Japan Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 161 Japan Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 162 Japan Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 163 Japan Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 164 Japan Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 165 Japan Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 166 Japan Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 167 India Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 168 India Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 169 India Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 170 India Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 171 India Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 172 India Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 173 India Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 174 India Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 175 South Korea Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 176 South Korea Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 177 South Korea Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 178 South Korea Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 179 South Korea Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 180 South Korea Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 181 South Korea Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 182 South Korea Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 183 South-East Asia Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 184 South-East Asia Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 185 South-East Asia Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 186 South-East Asia Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 187 South-East Asia Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 188 South-East Asia Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 189 South-East Asia Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 190 South-East Asia Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 191 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 192 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 193 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 194 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 195 Rest of Asia Pacific Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 196 Rest of Asia Pacific Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 197 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 198 Rest of Asia Pacific Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 199 Latin America Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 200 Latin America Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 201 Latin America Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 202 Latin America Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 203 Latin America Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 204 Latin America Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 205 Latin America Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 206 Latin America Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 207 Latin America Oncology Small Molecule Drug Market, by Country, 2017-2022 (US$ Bn)
TABLE 208 Latin America Oncology Small Molecule Drug Market, by Country, 2023-2030 (US$ Bn)
TABLE 209 Brazil Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 210 Brazil Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 211 Brazil Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 212 Brazil Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 213 Brazil Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 214 Brazil Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 215 Brazil Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 216 Brazil Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 217 Argentina Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 218 Argentina Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 219 Argentina Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 220 Argentina Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 221 Argentina Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 222 Argentina Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 223 Argentina Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 224 Argentina Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 225 Rest of Latin America Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 226 Rest of Latin America Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 227 Rest of Latin America Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 228 Rest of Latin America Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 229 Rest of Latin America Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 230 Rest of Latin America Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 231 Rest of Latin America Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 232 Rest of Latin America Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 233 Middle East and Africa Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 234 Middle East and Africa Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 235 Middle East and Africa Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 236 Middle East and Africa Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 237 Middle East and Africa Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 238 Middle East and Africa Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 239 Middle East and Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 240 Middle East and Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 241 Middle East and Africa Oncology Small Molecule Drug Market, by Country, 2017-2022 (US$ Bn)
TABLE 242 Middle East and Africa Oncology Small Molecule Drug Market, by Country, 2023-2030 (US$ Bn)
TABLE 243 GCC Countries Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 244 GCC Countries Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 245 GCC Countries Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 246 GCC Countries Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 247 GCC Countries Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 248 GCC Countries Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 249 GCC Countries Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 250 GCC Countries Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 251 South Africa Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 252 South Africa Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 253 South Africa Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 254 South Africa Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 255 South Africa Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 256 South Africa Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 257 South Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 258 South Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)
TABLE 259 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Drug Class, 2017-2022 (US$ Bn)
TABLE 260 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Drug Class, 2023-2030 (US$ Bn)
TABLE 261 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Indication, 2017-2022 (US$ Bn)
TABLE 262 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Indication, 2023-2030 (US$ Bn)
TABLE 263 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by RoA, 2017-2022 (US$ Bn)
TABLE 264 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by RoA, 2023-2030 (US$ Bn)
TABLE 265 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2017-2022 (US$ Bn)
TABLE 266 Rest of Middle East and Africa Oncology Small Molecule Drug Market, by Distribution Channel, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global oncology small molecule drug market?

The global oncology small molecule drug market was valued at USD 76.5 Billion in 2022.

What is the expected growth rate of the oncology small molecule drug market between 2023 and 2030?

The oncology small molecule drug market is expected to grow at a CAGR of 5.80% between 2023 and 2030, reaching USD 113.51 Billion in 2030.

Which segment is leading the market share among the drug class?

Targeted therapy drug is the leading segment by drug class, holding around half the share in value in 2022.

Which distribution channel governs the demand for oncology small molecule drugs worldwide?

The hospital pharmacies segment governs the demand for oncology small molecule drugs worldwide, holding a massive share of nearly 55% in 2022.

Which segment is expected to post the highest CAGR during the forecast period?

The retail pharmacies segment is expected to post the highest CAGR during the forecast period.

Which region is fueling the growth of the oncology small molecule drug industry?

North America is fueling the growth of the oncology small molecule drug industry, with a nearly two-fifth share in 2022.

Who is the major global oncology small molecule drug market players?

The top players include Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development LLC, Novartis AG, Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., Emcure Pharmaceuticals Ltd., AstraZeneca, Kyowa Kirin Inc., and HQ Specialty Pharma Corp and others

What is the major market driver of the oncology small molecule drug industry?

The Increasing prevalence of cancer worldwide is the major market driver.

What are the major market restraints of the oncology small molecule drug industry?

High cost of oncology small molecule drug development restraints of oncology small molecule drug industry.

What are the major market opportunities of the oncology small molecule drug industry?

Advances in molecular biology, genomics, and drug discovery techniques are opportunities for the oncology small molecule drug industry.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –